Adding Bevacizumab to Adjuvant Therapy of No Benefit in Colon Cancer

In fact, outcomes with bevacizumab trended toward inferior disease-free and overall survival.

Adjuvant chemotherapy with a fluorinated pyrimidine combined with oxaliplatin is standard treatment for stage III colon cancer. The vascular endothelial growth factor (VEGF)–targeted agent bevacizumab combined with first-and second-line chemotherapy improves disease-free survival and, in some studies, overall survival in patients with advanced disease. However, in the recent National Surgical Adjuvant Breast and Bowel Project C-08 trial (J Clin Oncol 2011; 29:11), the addition of bevacizumab to adjuvant chemotherapy in stage II and III colon cancer failed to improved outcomes.

To further evaluate the use of adjuvant chemotherapy plus bevacizumab in this setting, investigators conducted an industry-sponsored, multicenter, randomized, controll…

Reviewing Author

David H. Ilson, MD, PhD

Disclosures

Consultant/Advisory BoardAstraZeneca; Merck; Taiho; Astellas; Bristol Myers Squibb; Regeneron; Oncolys; Amgen; Daiichi Sankyo

David H. Ilson, MD, PhD

Disclosures

Consultant/Advisory BoardAstraZeneca; Merck; Taiho; Astellas; Bristol Myers Squibb; Regeneron; Oncolys; Amgen; Daiichi Sankyo